Efficacy of Rabeprazole-based Versus Therapy on Helicobacter Pylori Positive Peptic Ulcer with Lansoprazole-based Triple

Objective: To compare the efficacy of rabeprazole-based and lansoprazole-based triple therapy in the treatment of Helicobacter pylori (H pylori) -positive peptic ulcer. Methods: Eighty-three patients with H pylori positive peptic ulcers were randomized into two groups: the 1st group treated with rabeprazole 10 mg bid (rabeprazole-group n=41) and the 2nd group treated with lansoprazole 20 mg bid (lansoprazole-group n=42) for 1 week, all patients were given amoxicillin 1g bid and metronidazole 400mg for one week after. Clinical symptoms were observed and recorded weekly. One month after treatment, the eradication rate of H pylori and the healing rate of peptic ulcer were evaluated according to result of repeated endoscope. Results: The relief rate for clinical symptoms in rabeprazole-group and lansoprazole-group was 80% and 60% respectively at one day finishing regimen (P 0.05). The relief rate for clinical symptoms in both groups was 98% and 98% respectively at one week finishing regimen (P 0.05), the ulcer healing rate in both groups was 93% and 76% (P 0.05), the global effective rate in both groups was 98%and 96% respectively (P 0.05). And the H pylori eradication rate in both groups was 85% and 81% respectively (P 0.05). Conclusion: Both regimens are effective for curing peptic ulcer, relieving symptoms, and for eradicating H pylor. Rabeprazole-based triple therapy is superior to lansoprazole-based triple therapy in improving symptoms and curing ulcers.